The “Stepping Stone” Approach to Getting Longevity Drugs to Market - proto.life
proto.life · 1,933 words · saved by 1 readers
Getting geroprotective drugs to market for specific disease applications is the first step in eventually making them available for healthier aging.
The “Stepping Stone” Approach to Getting Longevity Drugs to Market Getting geroprotective drugs to market for specific disease applications is the first step in eventually making them available for healthier aging. By Jason Socrates Bardi Illustrations by Nathalie Lees Share Share on Twitter Share on Facebook Go Deeper Business Drugs Longevity Medicine The silver tsunami is coming. By 2050, the number of people in the world over the age 60 will double, making up a fifth of the world’s population. Two-thirds of them will live in low-income and middle-income countries but health systems and econ
related reading
- What the Aging Field Needs - Celine Haliouacelinehh.com
- Bottlenecks of Aging - Amaranth Foundationamaranth.foundation
- What we wish we knew entering the aging fieldlibrariesforthefuture.bio
- Where are all the trillion dollar biotechs?ladanuzhna.xyz
- My Aging Thesis — Celine Haliouacelinehh.com
- Nintil - How to solve agingnintil.com
- The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogatelfo.github.io
- NewLimit raises $435M led by Founders Fund to bring longevity medicines to human trialsblog.newlimit.com
- Anti-Aging: State of the Art — LessWronglesswrong.com
- A primer on the current state of longevity researchowlposting.com
- Longevity FAQ - Laura Demingldeming.com
- Nintil - The Longevity FAQnintil.com